Arcutis Biotherapeutics (ARQT) Expected to Announce Quarterly Earnings on Tuesday

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) is expected to announce its Q1 2025 earnings results after the market closes on Tuesday, May 6th. Analysts expect Arcutis Biotherapeutics to post earnings of ($0.19) per share and revenue of $64.80 million for the quarter.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.19. The firm had revenue of $71.36 million during the quarter, compared to the consensus estimate of $60.52 million. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%. On average, analysts expect Arcutis Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Arcutis Biotherapeutics Stock Down 1.2 %

NASDAQ ARQT traded down $0.18 during trading hours on Tuesday, reaching $14.36. 238,792 shares of the company traded hands, compared to its average volume of 2,342,754. The stock has a market capitalization of $1.70 billion, a PE ratio of -8.02 and a beta of 1.67. The company has a current ratio of 2.46, a quick ratio of 2.38 and a debt-to-equity ratio of 0.67. Arcutis Biotherapeutics has a 12 month low of $6.99 and a 12 month high of $17.75. The company has a 50 day moving average of $14.51 and a two-hundred day moving average of $12.93.

Insider Buying and Selling

In other news, insider Todd Franklin Watanabe sold 1,500 shares of the stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $17.52, for a total value of $26,280.00. Following the completion of the transaction, the insider now directly owns 927,414 shares of the company's stock, valued at approximately $16,248,293.28. This represents a 0.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Masaru Matsuda sold 8,338 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $12.70, for a total transaction of $105,892.60. Following the completion of the transaction, the insider now owns 178,692 shares in the company, valued at approximately $2,269,388.40. This trade represents a 4.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 46,099 shares of company stock valued at $631,256 over the last three months. 9.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on ARQT shares. Needham & Company LLC reaffirmed a "buy" rating and set a $20.00 price objective on shares of Arcutis Biotherapeutics in a research report on Wednesday, April 9th. Guggenheim restated a "buy" rating on shares of Arcutis Biotherapeutics in a research report on Thursday, April 3rd. The Goldman Sachs Group increased their target price on shares of Arcutis Biotherapeutics from $13.00 to $15.00 and gave the company a "neutral" rating in a research note on Thursday, February 27th. HC Wainwright restated a "buy" rating and issued a $19.00 price target on shares of Arcutis Biotherapeutics in a research report on Thursday, April 3rd. Finally, Jefferies Financial Group raised their price objective on Arcutis Biotherapeutics from $16.00 to $19.00 and gave the stock a "buy" rating in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $18.80.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.